Purpose: Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific inhibitors.
INTRODUCTION
Rhabdoid tumors are highly aggressive and therapy-resistant embryonal tumors. They can occur in a variety of anatomical sites and receive the generic name of malignant rhabdoid tumors (MRTs). Rhabdoid tumors were first described in the kidney, where they received the name of rhabdoid tumor of the kidney or RTK. It is now known that the most frequent primary location is the brain, where they are called atypical teratoid/rhabdoid tumors (AT/RTs). Rhabdoid tumors originating at all sites are recognized as the same entity due to their similar morphology, aggressive clinical behavior, and common genetic abnormalities. 1 Tumors originating from different locations share the same biologic and clinical characteristics; however, low overlap in gene expression (GE) of AT/RTs and RTK has been recently demonstrated. 2 Furthermore, pan-omics analyses have recently established that there are molecularly defined subgroups of tumors within rhabdoid tumors. [3] [4] [5] The large majority of rhabdoid tumors demonstrate genomic alterations of the SMARCB1 (INI1/BAF47/hSNF5) gene or, to a lesser extent, the SMARCA4 (BRG1) gene. 6 Both genes are components of the SWI/SNF chromatin-remodeling complex. 7 AT/RTs are the most common malignant central nervous system (CNS) tumors of children below 6 months of age. 8 Approximately 70%
of all cases arise in children younger than 1 year of age, and over 90% of cases occur before 3 years of age. Overall survival is poor, with median survival of about 17 months. 9 Recently, intensive multimodality treatment combining maximal safe surgery, craniospinal irradiation, and intensive chemotherapy has provided survival improvement.
However, treatment-related toxicity is high. Moreover, young age and involvement of critical structures within the CNS limits the use of this approach. 8 Furthermore, over 70% of children with extracranial MRT express nonlocalized disease at the time of diagnosis and traditional chemotherapy is largely ineffective. 10 In this scenario, more effective and less toxic therapeutic options are needed.
Protein kinases are key regulators of cell function. They mediate most of the signal transduction in eukaryotic cells and coordinate the activity of multiple cellular processes including metabolism, transcription, cell cycle progression, cell movement, differentiation, and apoptosis. They direct the activity, localization, and overall function of many proteins by modifying protein activity, though adding phosphate groups to their substrate. 11 The human kinome comprises at least 518 protein kinases, of which 478 belong to one superfamily whose catalytic domains are related in sequence. 11, 12 Mutations and dysregulation of protein kinases play causal roles in human disease, particularly cancer. 12, 13 Their involvement in multiple aspects of cell biology opens the possibility of developing agonists and antagonists for therapeutic use. In fact, a growing interest in developing orally active protein kinase inhibitors has led to the approval of several inhibitors for clinical use. 14 We hypothesized that a systematic functional screening of the kinome will allow an accurate study of the kinase-dependent rhabdoid tumor phenotype and, therefore, have the potential to reveal new potential therapeutic targets.
To test this hypothesis, we used clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9). The CRISPR/Cas9 system is a powerful gene-editing technology and recognized as "the biggest game changer to hit biology since PCR." 15 For gene editing, two components must be expressed in the cells: the Cas9 nuclease and a guide RNA (gRNA) that directs Cas9 to a specific target DNA site using standard RNA-DNA complementarity base pairing. After DNA binding, DNA double-strand breaks (DSBs) are created in the targeted area. These DSBs are then repaired by nonhomologous end joining, which frequently results in gene disruption. [16] [17] [18] [19] [20] It has been shown that genome-wide screens can be accomplished with pools of lentivirus. Instead of a typical "pooled" screening approach, where gRNAs for multiple genes are delivered together, we used an "arrayed" screening approach focused in the kinome. Arrayed were established from an abdominal rhabdoid tumor. [24] [25] [26] The G401 cell line (ATCC, USA) was established from a RTK. AT/RT cell lines BT-12 and BT-16, which have been extensively used in preclinical studies, 27, 28 were established by Drs. Houghton and Biegel (Nationwide Children's Hospital, Columbus, Ohio, and The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, respectively) and provided to us by Dr. Hashizume (Northwestern University Feinberg School of Medicine, Chicago, Illinois). 29 As a negative control, we used HFF-SCC058 cells (EDM Millipore, USA) derived from human foreskin fibroblasts, which have significantly lower expression of Pololike kinase 4 (PLK4) (Fig. 4C) . MON, BT-12, and BT-16 cells were maintained in HyClone RPMI 1640 (GE Healthcare Life Sciences, USA), G401 in McCoy's 5A (Sigma-Aldrich, USA), and HFF-SCC058 in DMEM (Thermo Fisher Scientific, USA). All were supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 • C, 5% CO 2 .
CRISPR screening
We performed a partial screening of the kinome by editing 160 kinase genes individually (Supplementary 
Gene editing evaluation

Gene cleavage detection
Gene editing was evaluated by genome cleavage detection (GCD) assay using GeneArt R Genomic Cleavage Detection Kit (Thermo Fisher Scientific, USA), a method that detects locus-specific DSB formation by direct polymerase chain reaction (PCR) amplification and endonuclease activity that cuts specifically at hetero-duplex mismatches. Table S3 ). Table S4 ). GE profiling was performed using Illumina HT-12v.4 BeadChip whole-genome expression arrays (Illumina, USA). 30 
Next-generation sequencing
Microarray GE profiling
Quantitative real-time PCR
The expression of PLK4 (Hs00179514_m1) was verified by TaqMan GE assays (Thermo Fisher Scientific, USA) using the housekeeping gene GAPDH (Hs02758991_g1) as reference as previously described. 30 
PLK4 inhibitor
The cytotoxic effects of the PLK4 inhibitor CFI-400945 (CAS1338800-06-8-Cayman Chemical, USA) [31] [32] [33] were tested in MON, G401, BT-12, and BT-16 cells. Cell proliferation was evaluated by MTT assay and cell survival was evaluated by clonogenic assays using increasing concentrations of the drug in different time-points, as described below.
Proliferation assays 2.7.1 MTT assay
To evaluate cell proliferation, we used TACS MTT Cell Proliferation Assays (Trevigen, USA). We plated 2 × 10 3 cells on each well of a 96-well plate and the absorbance was measured after 48 and 72 hr at concentrations of 10, 50, 100, 200, and 500 nM. Each experiment was performed in triplicates.
Flow cytometry
MON-Cas9 and MON-PLK4-mutated cells were evaluate for the impact of the mutation over the cell cycle by staining the cells with propidium iodide (Thermo Fisher Scientific, USA). Cells were then subjected to flow cytometric analysis using a BD Fortessa instrument (BD Biosciences, USA). Data was analyzed using Modfit LT from Verity Software House. Experiments were performed in triplicates.
Immunohistochemistry
Formalin-fixed paraffin-embedded 5-m thick sections from cell blocks of MON-Cas9 and MON-PLK4-mutated cells were stained using standard immunohistochemical methods. For proliferation analysis, we evaluated Ki-67 and phospho-histone H3 (PHH3) immunostaining.
Positive cells for Ki-67 and PHH3 were counted in five fields with 40× magnification using ImageJ software. 34 
Invasion and migration assays
Both migration and invasion were assessed using a 24-well Transwell chamber system (Corning, USA). 35 MON cells were plated at 20,000
per well for cell migration and at 50,000 per well coated with matrigel (200 g/ml, 3 hr of solidification) for cell invasion. HFF-SCC058 cells were used as negative controls. Cells were treated with either 100 nM of CFI-400945 or 0.1% dimethyl sulfoxide (DMSO), incubated for 24 hr, fixed with formalin, stained by Cresyl violet (ACROS Organics, USA), and counted using an inverted microscope. All experiments were performed in triplicates.
Clonogenic assay
For each cell line, 200 cells were seeded into six-well plates, incubated for 14 days, fixed with formalin, stained with Cresyl violet (ACROS 4 (due to the close proximity, the same primer sets could be used): F2-GCCACTGTTCTACTACAGTGCT; R2-CCATGTGCACTTCGAGTGGCAA. For NGS, the illustration of more than 90,000 reads across this region is shown in a compressed plot. Each "line" in the panels "PLK4.1" and "PLK4.2-4" represents a single NGS read, where the "gray" matches the expected sequence, black represents a deletion, and red (T), green (A), blue (C), and gold (G) represent nucleotide insertions. In the region targeted by PLK4.1, few or no indels were observed (<5% of the reads), whereas in the regions targeted by "PLK4.2-4.4" a very high efficiency of indel formation was observed (positioned in the center of the plot, >55% of the reads), which were principally found at the PLK4. 
In vivo toxicity assay
The toxic effect of CFI-400945 to normal cells and to the whole 
RESULTS
Mutations in PLK4 significantly impaired rhabdoid tumor cell growth
Transductions with Lenti-CRISPR were highly efficient (Fig. 1A) . Monitoring the growth of each one of the 160 stably kinase-mutated cell 
(C) Analysis of SMARCB1
GE indicates downregulation in rhabdoid tumors and (E) the analysis of EZH2 GE indicates upregulation in rhabdoid tumors ( ** P < 0.01 and **** P < 0.0001, one-way ANOVA) as previously described in the literature. These data can be used as references for the PLK4 expression levels observed in our cohort of samples. Patients' data are described in Supplementary Table S4 lines demonstrated that deficiency in eight kinases (5%) resulted in significant impairment of cell proliferation. The greatest inhibition of proliferation was observed with gRNAs targeting PLK4. While MON wild-type and controls reached confluence in a 12-well plate after 7 days, MON-PLK4-mutated cells took over three times longer (22 days) (Fig. 1B) . Successful gene editing was demonstrated by GCD, NGS (Fig. 1C) , quantitative real-time polymerase chain reaction (qRT-PCR) (Fig. 1D) , and Western blot ( Supplementary Fig. S1 ). We confirmed the initial screening results by repeating CRISPR editing of those eight kinase genes and controls. These secondary results were consistent with the initial observations with the same eight kinase-mutated cells taking at least twice as long as the controls to reach confluence.
PLK4 gRNAs edited the PLK4 gene with high specificity
We have performed an analysis of the off-target sites for all PLK4 gRNAs based on degenerate nucleotide sequences. Only 48 sites of high homology were identified in the genome, and only three of them were located within coding regions. NGS sequencing with primers specific for each site demonstrated lack of off-target cleavage at all sites (Supplementary Table S3 and Supplementary Fig. S2 ).
PLK4 is overexpressed in MRTs, RTK, AT/RTs, and other embryonal brain tumors
To explore the pattern of PLK4 expression in rhabdoid tumors, we evaluated the microarray GE data of our collection of 116 samples (Supplementary Table S4 ). GE data from these microarray experiments have been previously validated by our group. 1, 30, 36 Our analysis demonstrated overexpression of PLK4 in RTK, AT/RTs, and additional embryonal brain tumors, when compared with other pediatric brain tumor types and normal brain tissue ( Fig. 2A) . The highest level of expression among our samples was observed in an intracranial neuroblastoma ( Fig. 2A and Supplementary Table S4) .
SMARCB1 and EZH2, previously reported to be significantly differentially expressed in rhabdoid tumors (down-and upregulated, respectively), 6, 37 were evaluated in our cohort of samples as references (Figs. 2C and 2D ).
PLK4 CRISPR-mutated MON cells showed decrease in proliferation and survival
MON-PLK4-mutated cells compared to MON-Cas9 ones demonstrated (a) significantly lower proliferative activity as assessed by immunohistochemistry (IHC) for Ki-67 (Fig. 3A) , by IHC for PHH3 (Fig. 3B) , and by flow cytometry cell cycle analysis (Fig. 3C) , and (b) significantly lower survival as detected by clonogenic assay (Fig. 3D) . (Fig. 4A ) and reduction in cell survival (Fig. 4C) . Remarkably, significant decrease in both cell migration and invasion was observed in MON-treated cells (Fig. 4D ). With a very low level of PLK4 expression detected by qRT-PCR (Fig. 4B ), no effect was observed over HFF-SCC058 cells.
CFI-400945 showed none to minimal toxic effects over zebrafish larvae
PLK4 is highly conserved across species. 40 Comparison of zebrafish Plk4 sequence to human ortholog indicated a highly conserved kinase domain with fully preserved four amino acids predicted to bind CFI-400945 in PLK4 active site 32 (Fig. 5A) . Such similarity indicates that zebrafish is a relevant model to test the effect of this drug on vertebrate development. We tested the toxicity of CFI-400945 at early larvae stage, when rapid organogenesis and growth take place, which is relevant for pediatric tumor therapy. After exposing over 400 larvae to a broad spectrum of drug concentration (10 nM to 20 M) for 3 days, no increase in larvae deaths was observed. In extremely high concentrations (10 and 20 M), edema and body curvature were consistently observed (Fig. 5B) . These results demonstrated that although the drug penetrated the larvae, it may be safe for use in therapeutic doses.
F I G U R E 4 Cytotoxic effects of CFI-400945 in vitro.
(A) Treatment with CFI-400945 resulted in significant reduction of cell proliferation in all cell lines evaluated as assessed by MTT assay ( * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001, two-way ANOVA). (B) Clonogenig assay analyzed 14 days after treatment with CFI-400945 showed complete absence of colonies when cells were exposed to the drug at concentrations of 50-200 nM ( **** P < 0.0001, two-way ANOVA). Left: representative images of colonies treated with DMSO; Right: representative images of colonies treated with 50 nM of CFI-400945. (C) qRT-PCR showed that HFF-SCC058 human fibroblasts had significantly lower PLK4 expression when compared with MON cells ( **** P < 0.0001, unpaired t-test). (D) Invasion and migration assays showed significant reduction in MON cells after 24 hr of treatment with 100 nM of the drug, while no effects were observed in HFF-SCC058 human fibroblasts ( * P < 0.05 and *** P < 0.001, two-way ANOVA)
DISCUSSION
In this study, we identified PLK4 as a new potential therapeutic target for rhabdoid tumors. The PLK family of serine/threonine kinases plays a critical role in regulation of mitosis. Mammalian cells express five Polo-kinase family members (PLK1-5). They share structurally similar amino-terminal catalytic domains and Polo-box motifs in the carboxyterminal domains. PLK4 is structurally divergent from the other PLK family members. Unlike the other Polo-like kinases, PLK4 has only one Polo box and an active site with high homology to the Aurora kinases.
PLK4 plays a key role in cell cycle control. It localizes to the centrosomes and is a critical regulator of centriole duplication. [40] [41] [42] [43] In normal conditions, PLK4 is expressed in proliferating tissues such as testis. Due to its essential role in cell proliferation, the activity of PLK4 is tightly autoregulated [44] [45] [46] as the correct number of centrosomes is critical for chromosome segregation during cell division. PLK4
has been described to be aberrantly expressed in cancer, [47] [48] [49] and Ko et al. demonstrated that PLK4 haploinsufficiency significantly increased the incidence of spontaneous liver and lung cancers in adult mice. 48 Sillibourne and Bornens demonstrated that the levels of active PLK4 increase toward the progression into the cell cycle. These levels are mirrored by the PLK4 mRNA levels, indicating that transcription has an important role in controlling the overall expression levels of active PLK4. 40 Our GE data show significantly higher PLK4 expression expression, the overall expression levels of PLK4 is low, meaning that slight changes in expression may have significant impact over the phenotype. This is the first time PLK4 has been described as a potential target for both brain and pediatric tumors.
Kinase inhibition has already shown to be promising in the treatment of rhabdoid tumors. 8 Inhibition of ERBB2 by lapatinib resulted in significant impairment of cell migration and initiation of apoptosis in rhabdoid tumor cell lines. 28, 50 Palbociclib, an inhibitor of the cyclindependent kinases 4 and 6, delayed the regrowth of irradiated AT/RT xenografts. 51 The proto-oncogene PLK1 is the most studied member of the PLK family. Morozov et al. observed that knocking down PLK1, which was shown to be downregulated in rhabdoid cells after SMARCB1 reintroduction, resulted in mitotic arrest, aberrant nuclear division, decreased survival, and induction of apoptosis. 52 Morozov et al. also showed that reintroduction of SMARCB1 into rhabdoid tumor cells resulted in repression of mitotic genes including Aurora kinase A (AURKA). 52 Later on, it was demonstrated that AURKA was a repressed effector target of SMARCB1, which repressed AURKA transcription in a cell-typespecific manner. 53 Notably, inhibition of AURKA resulted in decreased activity of pro-proliferative signaling pathways in AT/RT, 54 and treatment with the AURKA inhibitor alisertib resulted in high response rates in rhabdoid mouse xenograft models. 55 The AURKA inhibitor alisertib has shown to be active as a single agent in children with recurrent AT/RT, 56 and it is currently in phase II trial for rhabdoid tumor treatment.
The CFI-400945 is the first potent PLK4 inhibitor discovered. It has been demonstrated that CFI-400945 selectively inhibits PLK4 in cancer cells, and it has recently entered in phase I clinical trials for the treatment for solid tumors in adults. It has been observed that this drug had "certain activity" against Aurora kinase B due to structural similarities of their active binding sites. However, the drug exhibited no significant inhibition of AURKA or of other PLK family members. 32, 33 Here, we first demonstrated that editing of PLK4 resulted in significant impairment of proliferation and survival of MRT (MON) cells.
Then, we investigated the cytotoxic activity of the PLK4 inhibitor CFI-400945 over AT/RT, MRT, and RTK cells. We verified that the use of the drug, even in low concentrations, resulted in significant impact on tumor cell proliferation and survival. We now speculate that association of PLK4 inhibitor with AURKA inhibitor might be a beneficial combination treatment for patients with rhabdoid tumors.
Recently, Rosario et al. demonstrated that PLK4 is also involved in regulating cell spreading and motility promoting cell migration and may, therefore, be associated with cancer progression and death from metastasis in solid tumor patients. 41 Remarkably, we also demonstrated that CFI-400945 significantly impaired rhabdoid tumor cell migration and invasion while sparing non-neoplastic human fibroblasts. This is additional evidence that inhibiting PLK4 may be a path to successfully treat these highly metastatic pediatric tumors.
Finally, as our main target is the pediatric population, we tested the toxicity of CFI-400945 to the zebrafish development by exposing zebrafish larvae to increasing concentrations of the drug for extended periods of time. We observed that no embryo died from the effect of the drug, while extremely high concentrations resulted in edema.
Based on our observations and on data from the literature, we infer that only cells abnormally expressing PLK4 cells are susceptible to the effects of the inhibitor and therefore it may be safe to be used in pediatric patients. The mechanisms by which the PLK4 inhibitor seems to spare normal cells are still to be elucidated.
CONCLUSIONS
Our findings indicate that rhabdoid tumor cell proliferation is dependent on PLK4, as shown by genetic and pharmacologic intervention.
This suggests that PLK4 may function as a therapeutic target for MRT, RTK, AT/RT, and possibly other embryonal tumors of the brain.
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